CytomX announces filing of registration statement for proposed initial public offering of common stock

CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody™ therapeutics for the treatment of cancer, today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. CytomX intends to list its common stock under the symbol "CTMX" on the NASDAQ Global Market.

BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC will act as joint book-running managers for the offering. Oppenheimer & Co. will serve as manager for the offering.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

SOURCE CytomX Therapeutics